LBRX
LB Pharmaceuticals Inc Common StockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$725.47M
P/E Ratio
—
EPS
$-3.13
Beta
—
52W High
$27.55
52W Low
$13.36
50-Day MA
$23.89
200-Day MA
$19.89
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About LB Pharmaceuticals Inc Common Stock
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. The company is headquartered in New York, New York.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-29.18M |
| Operating Margin | 0.00% |
| Return on Equity | -15.70% |
| Return on Assets | -10.60% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $11.91 |
| Price-to-Book | 2.44 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $28.67M |
| Float | $15.33M |
| % Insiders | 0.27% |
| % Institutions | 94.96% |
Analyst Ratings
Consensus ($45.75 target)
1
Strong Buy3
BuyData last updated: 4/8/2026